Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets
about
Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?Tackling a novel lethal virus: a focus on H7N9 vaccine development.H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets.Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.Considerations for the rapid deployment of vaccines against H7N9 influenza.Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.Refining the approach to vaccines against influenza A viruses with pandemic potential.Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site.Animal models for influenza viruses: implications for universal vaccine developmentA live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals.An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellinGeneration and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer ProtectionGeneration and protective efficacy of a cold-adapted attenuated avian H9N2 influenza vaccine.Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 influenza A Virus in Cells.Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice.220 mutation in the hemagglutinin of avian influenza A (H7N9) virus alters antigenicity during vaccine strain development.Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy.A live attenuated vaccine prevents replication and transmission of H7N9 highly pathogenic influenza viruses in mammalsSystemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice
P2860
Q26783481-C5C93794-C40F-4A99-8CB8-482F038FAEF9Q30148631-E2BEC6E7-914E-4D91-B753-C1679630F192Q30196901-E9A02CC9-C4A2-443E-9CEA-B57622261BA8Q30203790-0B676E62-0CDC-4186-8828-5E8EE0DCB052Q30364635-8BC3D4F9-C9CA-4C7E-9140-A7BEDDFAD082Q30373843-2C8AEB24-1417-4D71-9DF7-CB8997D01FA4Q30381595-5724B97A-4952-4FBF-AC46-EAB93F961757Q30382351-AF6B2CFE-8875-4675-9B88-4258316F02EDQ30400507-A9234022-C9A4-43E9-923B-E881014C6F7DQ34809686-01D5726C-16E0-4426-B998-32458551AE55Q34991413-0F76DBD1-6325-446F-84FD-98F2D040AB44Q35474243-E3488D2A-8849-4FD4-9E6D-C97E0C8AE662Q35507796-CA624AB0-7ED4-46AE-B0C7-9F9586B80BCCQ35710438-1B38F1D1-15C6-4869-8E20-E80DABA58EEFQ35749381-9BB5A238-69EB-49A6-A681-745C828FFC5FQ35787563-0876B40A-BB6F-47C0-857A-E0C972FFD454Q36991414-131C3106-98E9-4DFB-AEE0-53357B5B1E23Q37125370-0BA6B95A-0543-427C-80F4-2AFFA02988E4Q38822536-D960C5CE-4964-4FC0-AF97-AC50D16F33DAQ41919615-36F9AA74-A8F0-4E79-8AF9-DA2ECF250881Q45325112-DD67201A-0F16-4FF1-B821-C2F791E6E7D7Q46666851-374C622D-AD59-4312-B93F-47F8C011DFECQ47558185-199C31CC-61C1-436F-BDB8-898A9244E3E4Q55260817-C96113D9-2FE1-4BA9-BE4C-6C887FB10A63Q55689231-743BF236-C7C2-4A5D-95C8-AF8F7E909A05Q56971807-12E4F9C3-1CCE-471A-8AB9-23FB42E47D72Q58802400-C629865B-F86E-4460-83EB-9A7928E79D71
P2860
Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@ast
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@en
type
label
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@ast
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@en
prefLabel
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@ast
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@en
P2093
P2860
P356
P1433
P1476
Development of a high-yield li ...... 7 wild-type viruses in ferrets
@en
P2093
Celia Santos
Mariana Baz
Myeisha Paskel
Yumiko Matsuoka
Zhongying Chen
P2860
P304
P356
10.1128/JVI.00100-14
P577
2014-04-09T00:00:00Z